Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
Oncolytics Biotech is presenting a trial-in-progress e-poster (No. 994eTiP) on the REO 033 study at the ESMO Congress 2026. REO 033 is a randomized Phase 2 study of pelareorep plus FOLFIRI and bevacizumab versus standard-of-care in second-line RAS-mutant MSS metastatic colorectal cancer, with 30 patients per arm and objective response rate as the primary endpoint.
Key figures
- Drug Name
- pelareorep
- Phase Of Trial
- Phase 2
- Study
- REO 033
- Indication
- second-line RAS-mutant MSS metastatic colorectal cancer
- Primary endpoint
- objective response rate (ORR)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.